These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

732 related items for PubMed ID: 19576910

  • 1. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
    Tamim MK, Samadi P, Morissette M, Grégoire L, Ouattara B, Lévesque D, Rouillard C, Di Paolo T.
    Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
    [Abstract] [Full Text] [Related]

  • 2. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.
    Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T.
    Mov Disord; 2006 Jan; 21(1):9-17. PubMed ID: 16127720
    [Abstract] [Full Text] [Related]

  • 3. Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
    Morissette M, Samadi P, Hadj Tahar A, Bélanger N, Di Paolo T.
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr 16; 34(3):446-54. PubMed ID: 20026151
    [Abstract] [Full Text] [Related]

  • 4. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T.
    Synapse; 2006 Sep 01; 60(3):239-50. PubMed ID: 16739115
    [Abstract] [Full Text] [Related]

  • 5. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N, Jourdain VA, Morissette M, Grégoire L, Di Paolo T.
    Neuropharmacology; 2014 Apr 01; 79():688-706. PubMed ID: 24456747
    [Abstract] [Full Text] [Related]

  • 6. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B, Crossman AR, Brotchie JM.
    Exp Neurol; 1999 Feb 01; 155(2):204-20. PubMed ID: 10072296
    [Abstract] [Full Text] [Related]

  • 7. Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
    Smith LA, Tel BC, Jackson MJ, Hansard MJ, Braceras R, Bonhomme C, Chezaubernard C, Del Signore S, Rose S, Jenner P.
    Mov Disord; 2002 Sep 01; 17(5):887-901. PubMed ID: 12360537
    [Abstract] [Full Text] [Related]

  • 8. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L, Frohna PA, Joyce JN, Schneider JS.
    Mov Disord; 1997 Mar 01; 12(2):148-58. PubMed ID: 9087972
    [Abstract] [Full Text] [Related]

  • 9. Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias.
    Ouattara B, Hoyer D, Grégoire L, Morissette M, Gasparini F, Gomez-Mancilla B, Di Paolo T.
    Neuroscience; 2010 Jun 02; 167(4):1160-7. PubMed ID: 20303391
    [Abstract] [Full Text] [Related]

  • 10. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N, Martín AB, Mendialdua A, Moratalla R.
    Biol Psychiatry; 2006 Jan 01; 59(1):64-74. PubMed ID: 16139809
    [Abstract] [Full Text] [Related]

  • 11. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
    Van De Witte SV, Groenewegen HJ, Voorn P.
    Synapse; 2002 Jan 01; 43(1):1-11. PubMed ID: 11746728
    [Abstract] [Full Text] [Related]

  • 12. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
    Morin N, Morissette M, Grégoire L, Gomez-Mancilla B, Gasparini F, Di Paolo T.
    Neuropharmacology; 2013 Oct 01; 73():216-31. PubMed ID: 23756168
    [Abstract] [Full Text] [Related]

  • 13. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys.
    Chen L, Togasaki DM, Langston JW, Di Monte DA, Quik M.
    Neuroscience; 2005 Oct 01; 132(2):409-20. PubMed ID: 15802193
    [Abstract] [Full Text] [Related]

  • 14. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists.
    Morissette M, Grondin R, Goulet M, Bédard PJ, Di Paolo T.
    J Neurochem; 1999 Feb 01; 72(2):682-92. PubMed ID: 9930741
    [Abstract] [Full Text] [Related]

  • 15. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP, Fox SH, Johnston T, Reyes G, Millan MJ, Brotchie JM.
    Neurobiol Dis; 2009 Aug 01; 35(2):184-92. PubMed ID: 19118628
    [Abstract] [Full Text] [Related]

  • 16. Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets.
    Tel BC, Zeng BY, Cannizzaro C, Pearce RK, Rose S, Jenner P.
    Neuroscience; 2002 Aug 01; 115(4):1047-58. PubMed ID: 12453478
    [Abstract] [Full Text] [Related]

  • 17. Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
    Samadi P, Grégoire L, Hadj Tahar A, Di Paolo T, Rouillard C, Bédard PJ.
    Neuropharmacology; 2005 Aug 01; 49(2):165-73. PubMed ID: 15996565
    [Abstract] [Full Text] [Related]

  • 18. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys.
    Hadj Tahar A, Grégoire L, Darré A, Bélanger N, Meltzer L, Bédard PJ.
    Neurobiol Dis; 2004 Mar 01; 15(2):171-6. PubMed ID: 15006686
    [Abstract] [Full Text] [Related]

  • 19. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Grégoire L, Samadi P, Graham J, Bédard PJ, Bartoszyk GD, Di Paolo T.
    Parkinsonism Relat Disord; 2009 Jul 01; 15(6):445-52. PubMed ID: 19196540
    [Abstract] [Full Text] [Related]

  • 20. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M, Goulet M, Calon F, Falardeau P, Blanchet PJ, Bédard PJ, Di Paolo T.
    Mol Pharmacol; 1996 Nov 01; 50(5):1073-9. PubMed ID: 8913337
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.